sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20250503sibmed-2434Research ArticleОБЗОРЫREVIEWSОсобенности экспрессии ингибиторных рецепторов на эффекторных и регуляторных Т-клетках в контексте терапии ингибиторами «контрольных точек» иммунного ответаPeculiarities of inhibitory receptor expression on effector and regulatory T cells in the context of immune checkpoint inhibitor therapyhttps://orcid.org/0000-0003-2902-9336БаторовЕ. В.BatorovE. V.

Баторов Егор Васильевич, к.м.н.

630099, г. Новосибирск, ул. Ядринцевская, 14

630090, г. Новосибирск, ул. Пирогова, 1

Egor V. Batorov, candidate of medical sciences

630099, Novosibirsk, Yadrintsevskaya st., 14

630090, Novosibirsk, Pirogova st., 1

e.batorov@g.nsu.ruhttps://orcid.org/0009-0000-1100-9826ВасильченкоП. В.VasilchenkoP. V.

Васильченко Полина Вячеславовна

630099, г. Новосибирск, ул. Ядринцевская, 14

630090, г. Новосибирск, ул. Пирогова, 1

Polina V. Vasilchenko

630099, Novosibirsk, Yadrintsevskaya st., 14

630090, Novosibirsk, Pirogova st., 1

https://orcid.org/0000-0003-2346-6279ЧерныхЕ. Р.ChernykhE. R.

Черных Елена Рэмовна, д.м.н., проф., чл.-корр. РАН

630099, г. Новосибирск, ул. Ядринцевская, 14

Elena R. Chernykh, doctor of medical sciences, professor, corresponding member of the RAS

630099, Novosibirsk, Yadrintsevskaya st., 14

ct_lab@mail.ruНИИ фундаментальной и клинической иммунологии; Новосибирский государственный университетРоссияResearch Institute of Fundamental and Clinical Immunology; Novosibirsk State UniversityRussian FederationНИИ фундаментальной и клинической иммунологииРоссияResearch Institute of Fundamental and Clinical ImmunologyRussian Federation2025041120254552737Copyright © Баторов Е.В., Васильченко П.В., Черных Е.Р., 20252025Баторов Е.В., Васильченко П.В., Черных Е.Р.Batorov E.V., Vasilchenko P.V., Chernykh E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/2434

Ингибиторные рецепторы PD-1, TIM-3, LAG-3 и др. – «контрольные точки» иммунного ответа (immune checkpoint, «чек-пойнт») – экспрессируются активированными эффекторными Т-лимфоцитами с целью ограничения интенсивности иммунного ответа. В условиях хронического инфекционного процесса и при опухолевом росте чек-пойнт-рецепторы экспрессируют Т-клетки в состоянии «истощения» (T cell exhaustion), характеризующемся снижением их пролиферативной, цитотоксической и цитокин-продуцирующей активности. Восстановление функциональной активности Т-клеток лежит в основе механизма действия терапевтических моноклональных антител – «чек-пойнт-ингибиторов», таких как анти-PD-1/PD-L1 и анти-LAG-3, используемые в противоопухолевой терапии. В то же время чек-пойнт-рецепторы экспрессируют многие другие популяции клеток, в том числе регуляторные Т-клетки (Т-рег), супрессирующие реакции иммунного ответа. Данные о функциях ингибиторных рецепторов на Т-рег продолжают изучаться. В настоящей публикации мы приводим современные представления об экспрессии ингибиторных чек-пойнт-рецепторов популяциями Т-рег и их связи с эффектами терапии чек-пойнт-ингибиторами.

Inhibitory receptors PD-1, TIM-3, LAG-3, etc. – “immune checkpoints” – are expressed by activated effector T cells in order to limit the intensity of the immune response. Under the conditions of chronic infectious process and tumor growth, checkpoint receptors are expressed by T lymphocytes in a state of T cell exhaustion, characterized by a decrease in its proliferative, cytotoxic and cytokine-producing activity. Restoring the functional activity of T cells underlies the mechanism of action of therapeutic monoclonal antibodies – “checkpoint inhibitors”, such as anti-PD-1/PD-L1 and antiLAG-3 used in antitumor therapy. At the same time, checkpoint receptors are expressed by multiple cell populations, including regulatory T cells (T-regs), which suppress immune response. Data on the functions of inhibitory receptors on T-reg continue to be studied. In this article, we provide the recent knowledge on T-reg populations’ expression of inhibitory checkpoint receptors and how these relate to checkpoint inhibitor therapy’s outcomes.

Т-клеточное истощениеанти-PD-1/PD-L1 моноклональные антителаPD-1TIM-3LAG-3TIGITрегуляторные Т-клеткиT cell exhaustionanti-PD-1/PD-L1 monoclonal antibodiesPD-1TIM-3LAG-3TIGITregulatory T cellsИсследование выполнено за счет гранта Российского научного фонда № 20-75-10132-П.The study was funded by the Russian Science Foundation project № 20-75-10132-P.ReferencesGellrich F.F., Schmitz M., Beissert S., Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J. Clin. Med. 2020;9(1):223. doi: 10.3390/jcm9010223Gellrich F.F., Schmitz M., Beissert S., Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J. Clin. Med. 2020;9(1):223. doi: 10.3390/jcm9010223Fitzsimmons T.S., Singh N., Walker T.D.J., Newton C., Evans D.G.R., Crosbie E.J., Ryan N.A.J. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. Front. Med. (Lausanne). 2023;10:1192762. doi: 10.3389/fmed.2023.1192762Fitzsimmons T.S., Singh N., Walker T.D.J., Newton C., Evans D.G.R., Crosbie E.J., Ryan N.A.J. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. Front. Med. (Lausanne). 2023;10:1192762. doi: 10.3389/fmed.2023.1192762Sun C., Chen H., Wang Y., Zheng C. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin’s lymphoma: a systematic review and meta-analysis of 20 prospective studies. Hematology. 2023;28(1):2181749. doi: 10.1080/16078454.2023.2181749Sun C., Chen H., Wang Y., Zheng C. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin’s lymphoma: a systematic review and meta-analysis of 20 prospective studies. Hematology. 2023;28(1):2181749. doi: 10.1080/16078454.2023.2181749Lin N., Song Y., Zhu J. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Chin. J. Cancer Res. 2020;32(3):303–318. doi: 10.21147/j.issn.1000-9604.2020.03.03Lin N., Song Y., Zhu J. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Chin. J. Cancer Res. 2020;32(3):303–318. doi: 10.21147/j.issn.1000-9604.2020.03.03Das S., Johnson D.B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer. 2019;7(1):306. doi: 10.1186/s40425-019-0805-8Das S., Johnson D.B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer. 2019;7(1):306. doi: 10.1186/s40425-019-0805-8Hamanishi J., Mandai M., Matsumura N., Abiko K., Baba T., Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol. 2016;21(3):462–473. doi: 10.1007/s10147-016-0959-zHamanishi J., Mandai M., Matsumura N., Abiko K., Baba T., Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol. 2016;21(3):462–473. doi: 10.1007/s10147-016-0959-zSimon S., Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828. doi: 10.1080/2162402X.2017.1364828Simon S., Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828. doi: 10.1080/2162402X.2017.1364828Kinter A.L., Godbout E.J., McNally J.P., Sereti I., Roby G.A., O’Shea M.A., Fauci A.S. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 2008;181(10):6738–6746. doi: 10.4049/jimmunol.181.10.6738Kinter A.L., Godbout E.J., McNally J.P., Sereti I., Roby G.A., O’Shea M.A., Fauci A.S. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 2008;181(10):6738–6746. doi: 10.4049/jimmunol.181.10.6738Mujib S., Jones R.B., Lo C., Aidarus N., Clayton K., Sakhdari A., Benko E., Kovacs C., Ostrowski M.A. Antigen-independent induction of Tim-3 expression on human T cells by the common г-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J. Immunol. 2012;188(8):3745– 3756. doi: 10.4049/jimmunol.1102609Mujib S., Jones R.B., Lo C., Aidarus N., Clayton K., Sakhdari A., Benko E., Kovacs C., Ostrowski M.A. Antigen-independent induction of Tim-3 expression on human T cells by the common г-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J. Immunol. 2012;188(8):3745– 3756. doi: 10.4049/jimmunol.1102609Batorov E.V., Ineshina A.D., Aristova T.A., Denisova V.V., Sizikova S.A., Batorova D.S., Ushakova G.Y., Shevela E.Y., Chernykh E.R. PD-1+ and TIM3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. Oncology Research. 2024;32(10):1575–1587. doi: 10.32604/or.2024.047893Batorov E.V., Ineshina A.D., Aristova T.A., Denisova V.V., Sizikova S.A., Batorova D.S., Ushakova G.Y., Shevela E.Y., Chernykh E.R. PD-1+ and TIM3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. Oncology Research. 2024;32(10):1575–1587. doi: 10.32604/or.2024.047893Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015;15(8):486–499. doi: 10.1038/nri3862Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015;15(8):486–499. doi: 10.1038/nri3862ElTanbouly M.A., Noelle R.J. Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey. Nat. Rev. Immunol. 2021;21(4):257–267. doi: 10.1038/s41577-020-00454-2ElTanbouly M.A., Noelle R.J. Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey. Nat. Rev. Immunol. 2021;21(4):257–267. doi: 10.1038/s41577-020-00454-2Franco F., Jaccard A., Romero P., Yu Y.R., Ho P.C. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2020;2(10):1001–1012. doi: 10.1038/s42255-020-00280-9Franco F., Jaccard A., Romero P., Yu Y.R., Ho P.C. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2020;2(10):1001–1012. doi: 10.1038/s42255-020-00280-9van der Leun A.M., Thommen D.S., Schumacher T.N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer. 2020;20(4):218–232. doi: 10.1038/s41568-019-0235-4van der Leun A.M., Thommen D.S., Schumacher T.N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer. 2020;20(4):218–232. doi: 10.1038/s41568-019-0235-4Abe B.T., Macian F. Uncovering the mechanisms that regulate tumor-induced T-cell anergy. Oncoimmunology. 2013;2(2):e22679. doi: 10.4161/onci.22679Abe B.T., Macian F. Uncovering the mechanisms that regulate tumor-induced T-cell anergy. Oncoimmunology. 2013;2(2):e22679. doi: 10.4161/onci.22679Verma V., Shrimali R.K., Ahmad S., Dai W., Wang H., Lu S., Nandre R., Gaur P., Lopez J., Sade-Feldman M., … Khleif S.N. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+ CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 2019;20(9):1231– 1243. doi: 10.1038/s41590-019-0441-yVerma V., Shrimali R.K., Ahmad S., Dai W., Wang H., Lu S., Nandre R., Gaur P., Lopez J., Sade-Feldman M., … Khleif S.N. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+ CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 2019;20(9):1231– 1243. doi: 10.1038/s41590-019-0441-yZhao Y., Shao Q., Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol. Immunol. 2020;17(1):27–35. doi: 10.1038/s41423-019-0344-8Zhao Y., Shao Q., Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol. Immunol. 2020;17(1):27–35. doi: 10.1038/s41423-019-0344-8Zhang J., He T., Xue L., Guo H. Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine. 2021;68:103409. doi: 10.1016/j.ebiom.2021.103409Zhang J., He T., Xue L., Guo H. Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine. 2021;68:103409. doi: 10.1016/j.ebiom.2021.103409Moreira A., Gross S., Kirchberger M.C., Erdmann M., Schuler G., Heinzerling L. Senescence markers: Predictive for response to checkpoint inhibitors. Int. J. Cancer. 2019;144(5):1147–1150. doi: 10.1002/ijc.31763Moreira A., Gross S., Kirchberger M.C., Erdmann M., Schuler G., Heinzerling L. Senescence markers: Predictive for response to checkpoint inhibitors. Int. J. Cancer. 2019;144(5):1147–1150. doi: 10.1002/ijc.31763Galluzzi L., Chan T.A., Kroemer G., Wolchok J.D., López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 2018;10(459):eaat7807. doi: 10.1126/scitranslmed.aat7807Galluzzi L., Chan T.A., Kroemer G., Wolchok J.D., López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 2018;10(459):eaat7807. doi: 10.1126/scitranslmed.aat7807Yarchoan M., Hopkins A., Jaffee E.M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 2017;377(25):2500–2501. doi: 10.1056/NEJMc1713444Yarchoan M., Hopkins A., Jaffee E.M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 2017;377(25):2500–2501. doi: 10.1056/NEJMc1713444Carbognin L., Pilotto S., Milella M., Vaccaro V., Brunelli M., Caliò A., Cuppone F., Sperduti I., Giannarelli D., Chilosi M., … Tortora G. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142. doi: 10.1371/journal.pone.0130142Carbognin L., Pilotto S., Milella M., Vaccaro V., Brunelli M., Caliò A., Cuppone F., Sperduti I., Giannarelli D., Chilosi M., … Tortora G. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142. doi: 10.1371/journal.pone.0130142Doroshow D.B., Bhalla S., Beasley M.B., Sholl L.M., Kerr K.M., Gnjatic S., Wistuba II., Rimm D.L., Tsao M.S., Hirsch F.R. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 2021;18(6):345–362. doi: 10.1038/s41571-021-00473-5Doroshow D.B., Bhalla S., Beasley M.B., Sholl L.M., Kerr K.M., Gnjatic S., Wistuba II., Rimm D.L., Tsao M.S., Hirsch F.R. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 2021;18(6):345–362. doi: 10.1038/s41571-021-00473-5Vranic S., Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol. Biomed. 2023;23(1):15–25. doi: 10.17305/bjbms.2022.7953Vranic S., Gatalica Z. PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol. Biomed. 2023;23(1):15–25. doi: 10.17305/bjbms.2022.7953Lu S., Stein J.E., Rimm D.L., Wang D.W., Bell J.M., Johnson D.B., Sosman J.A., Schalper K.A., Anders R.A., Wang H., … Taube J.M. Comparison of biomarker modalities for predicting response to PD-1/ PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. doi: 10.1001/jamaoncol.2019.1549Lu S., Stein J.E., Rimm D.L., Wang D.W., Bell J.M., Johnson D.B., Sosman J.A., Schalper K.A., Anders R.A., Wang H., … Taube J.M. Comparison of biomarker modalities for predicting response to PD-1/ PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. doi: 10.1001/jamaoncol.2019.1549Roemer M.G., Advani R.H., Ligon A.H., Natkunam Y., Redd R.A., Homer H., Connelly C.F., Sun H.H., Daadi S.E., Freeman G.J., … Shipp M.A. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J. Clin. Oncol. 2016;34(23):2690–2697. doi: 10.1200/JCO.2016.66.4482Roemer M.G., Advani R.H., Ligon A.H., Natkunam Y., Redd R.A., Homer H., Connelly C.F., Sun H.H., Daadi S.E., Freeman G.J., … Shipp M.A. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J. Clin. Oncol. 2016;34(23):2690–2697. doi: 10.1200/JCO.2016.66.4482Jelinek T., Mihalyova J., Kascak M., Duras J., Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;152(3):357–371. doi: 10.1111/imm.12788Jelinek T., Mihalyova J., Kascak M., Duras J., Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;152(3):357–371. doi: 10.1111/imm.12788Armengol M., Santos J.C., Fernández -Serrano M., Profitós-Pelejà N., Ribeiro M.L., Roué G. Immune-checkpoint inhibitors in B-cell lymphoma. Cancers (Basel). 2021;13(2):214. doi: 10.3390/cancers13020214Armengol M., Santos J.C., Fernández -Serrano M., Profitós-Pelejà N., Ribeiro M.L., Roué G. Immune-checkpoint inhibitors in B-cell lymphoma. Cancers (Basel). 2021;13(2):214. doi: 10.3390/cancers13020214Schoenfeld A.J., Hellmann M.D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443–455. doi: 10.1016/j.ccell.2020.03.017Schoenfeld A.J., Hellmann M.D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443–455. doi: 10.1016/j.ccell.2020.03.017Yin Q., Wu L., Han L., Zheng X., Tong R., Li L., Bai L., Bian Y. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. doi: 10.3389/fimmu.2023.1167975Yin Q., Wu L., Han L., Zheng X., Tong R., Li L., Bai L., Bian Y. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. doi: 10.3389/fimmu.2023.1167975Adashek J.J., Kato S., Ferrara R., Lo Russo G., Kurzrock R. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. 2020;25(2):94– 98. doi: 10.1634/theoncologist.2019-0636Adashek J.J., Kato S., Ferrara R., Lo Russo G., Kurzrock R. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. 2020;25(2):94– 98. doi: 10.1634/theoncologist.2019-0636Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood. 2006;108(3):804–811. doi: 10.1182/ blood-2006-02-002774Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood. 2006;108(3):804–811. doi: 10.1182/ blood-2006-02-002774Itahashi K., Irie T., Nishikawa H. Regulatory T-cell development in the tumor microenvironment. Eur. J. Immunol. 2022;52(8):1216–1227. doi: 10.1002/eji.202149358Itahashi K., Irie T., Nishikawa H. Regulatory T-cell development in the tumor microenvironment. Eur. J. Immunol. 2022;52(8):1216–1227. doi: 10.1002/eji.202149358Huppert L.A., Green M.D., Kim L., Chow C., Leyfman Y., Daud A.I., Lee J.C. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol. Immunol. 2022;19(1):33–45. doi: 10.1038/s41423-021-00742-4Huppert L.A., Green M.D., Kim L., Chow C., Leyfman Y., Daud A.I., Lee J.C. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol. Immunol. 2022;19(1):33–45. doi: 10.1038/s41423-021-00742-4Santegoets S.J., Dijkgraaf E.M., Battaglia A., Beckhove P., Britten C.M., Gallimore A., Godkin A., Gouttefangeas C., de Gruijl T.D., Koenen H.J., … van der Burg S.H. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol. Immunother. 2015;64(10):1271– 1286. doi: 10.1007/s00262-015-1729-xSantegoets S.J., Dijkgraaf E.M., Battaglia A., Beckhove P., Britten C.M., Gallimore A., Godkin A., Gouttefangeas C., de Gruijl T.D., Koenen H.J., … van der Burg S.H. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol. Immunother. 2015;64(10):1271– 1286. doi: 10.1007/s00262-015-1729-xFreeborn R.A., Strubbe S., Roncarolo M.G. Type 1 regulatory T cell-mediated tolerance in health and disease. Front. Immunol. 2022;13:1032575. doi: 10.3389/fimmu.2022.1032575Freeborn R.A., Strubbe S., Roncarolo M.G. Type 1 regulatory T cell-mediated tolerance in health and disease. Front. Immunol. 2022;13:1032575. doi: 10.3389/fimmu.2022.1032575Roncarolo M.G., Gregori S., Bacchetta R., Battaglia M., Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity. 2018;49(6):1004– 1019. doi: 10.1016/j.immuni.2018.12.001Roncarolo M.G., Gregori S., Bacchetta R., Battaglia M., Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity. 2018;49(6):1004– 1019. doi: 10.1016/j.immuni.2018.12.001Deng G. Tumor-infiltrating regulatory T cells: origins and features. Am. J. Clin. Exp. Immunol. 2018;7(5):81–87.Deng G. Tumor-infiltrating regulatory T cells: origins and features. Am. J. Clin. Exp. Immunol. 2018;7(5):81–87.Paluskievicz C.M., Cao X., Abdi R., Zheng P., Liu Y., Bromberg J.S. T regulatory cells and priming the suppressive tumor microenvironment. Front. Immunol. 2019;10:2453. doi: 10.3389/fimmu.2019.02453Paluskievicz C.M., Cao X., Abdi R., Zheng P., Liu Y., Bromberg J.S. T regulatory cells and priming the suppressive tumor microenvironment. Front. Immunol. 2019;10:2453. doi: 10.3389/fimmu.2019.02453Fang R., Xie C., Long Y., Zhang C., Zhang Z., Chen L., Wei Y. Significance of peripheral blood Tregs in tumor: a narrative review. Ann. Blood 2020;5:34. doi: 10.21037/aob-20-53Fang R., Xie C., Long Y., Zhang C., Zhang Z., Chen L., Wei Y. Significance of peripheral blood Tregs in tumor: a narrative review. Ann. Blood 2020;5:34. doi: 10.21037/aob-20-53Shang B., Liu Y., Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep. 2015;5:15179. doi: 10.1038/srep15179Shang B., Liu Y., Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep. 2015;5:15179. doi: 10.1038/srep15179Kos K., de Visser K.E. The multifaceted role of regulatory T cells in breast cancer. Annu. Rev. Cancer Biol. 2021;5:291–310. doi: 10.1146/annurev-cancerbio-042920-104912Kos K., de Visser K.E. The multifaceted role of regulatory T cells in breast cancer. Annu. Rev. Cancer Biol. 2021;5:291–310. doi: 10.1146/annurev-cancerbio-042920-104912Martinez L.M., Robila V., Clark N.M., Du W., Idowu M.O., Rutkowski M.R., Bos P.D. Regulatory T cells control the switch from in situ to invasive breast cancer. Front. Immunol. 2019;10:1942. doi: 10.3389/fimmu.2019.01942Martinez L.M., Robila V., Clark N.M., Du W., Idowu M.O., Rutkowski M.R., Bos P.D. Regulatory T cells control the switch from in situ to invasive breast cancer. Front. Immunol. 2019;10:1942. doi: 10.3389/fimmu.2019.01942Zhang Y., Lazarus J., Steele N.G., Yan W., Lee H.J., Nwosu Z.C., Halbrook C.J., Menjivar R.E., Kemp S.B., Sirihorachai V.R., … Pasca di Magliano M. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020;10(3):422–439. doi: 10.1158/2159-8290.CD-19-0958Zhang Y., Lazarus J., Steele N.G., Yan W., Lee H.J., Nwosu Z.C., Halbrook C.J., Menjivar R.E., Kemp S.B., Sirihorachai V.R., … Pasca di Magliano M. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020;10(3):422–439. doi: 10.1158/2159-8290.CD-19-0958Raimondi G., Shufesky W.J., Tokita D., Morelli A.E., Thomson A.W. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J. Immunol. 2006;176(5):2808–2816. doi: 10.4049/jimmunol.176.5.2808Raimondi G., Shufesky W.J., Tokita D., Morelli A.E., Thomson A.W. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J. Immunol. 2006;176(5):2808–2816. doi: 10.4049/jimmunol.176.5.2808Gautron A.S., Dominguez-Villar M., de Marcken M., Hafler D.A. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur. J. Immunol. 2014;44(9):2703–2711. doi: 10.1002/eji.201344392Gautron A.S., Dominguez-Villar M., de Marcken M., Hafler D.A. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur. J. Immunol. 2014;44(9):2703–2711. doi: 10.1002/eji.201344392Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., Hipkiss E.L., Ravi S., Kowalski J., Levitsky H.I., … Vignali D.A. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–513. doi: 10.1016/j.immuni.2004.08.010Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., Hipkiss E.L., Ravi S., Kowalski J., Levitsky H.I., … Vignali D.A. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–513. doi: 10.1016/j.immuni.2004.08.010Joller N., Lozano E., Burkett P.R., Patel B., Xiao S., Zhu C., Xia J., Tan T.G., Sefik E., Yajnik V., … Kuchroo V.K. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569– 581. doi: 10.1016/j.immuni.2014.02.012Joller N., Lozano E., Burkett P.R., Patel B., Xiao S., Zhu C., Xia J., Tan T.G., Sefik E., Yajnik V., … Kuchroo V.K. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569– 581. doi: 10.1016/j.immuni.2014.02.012Camisaschi C., Casati C., Rini F., Perego M., de Filippo A., Triebel F., Parmiani G., Belli F., Rivoltini L., Castelli C. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J. Immu nol. 2010;184(11):6545–6551. doi: 10.4049/jimmunol.0903879Camisaschi C., Casati C., Rini F., Perego M., de Filippo A., Triebel F., Parmiani G., Belli F., Rivoltini L., Castelli C. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J. Immu nol. 2010;184(11):6545–6551. doi: 10.4049/jimmunol.0903879Yang Z.Z., Kim H.J., Wu H., Jalali S., Tang X., Krull J.E., Ding W., Novak A.J., Ansell S.M. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma. Clin. Cancer Res. 2020;26(19):5217–5231. doi: 10.1158/1078-0432.CCR-20-0558Yang Z.Z., Kim H.J., Wu H., Jalali S., Tang X., Krull J.E., Ding W., Novak A.J., Ansell S.M. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma. Clin. Cancer Res. 2020;26(19):5217–5231. doi: 10.1158/1078-0432.CCR-20-0558Banerjee H., Nieves-Rosado H., Kulkarni A., Murter B., McGrath K.V., Chandran U.R., Chang A., Szymczak-Workman A.L., Vujanovic L., Delgoffe G.M., Ferris R.L., Kane L.P. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021;36(11):109699. doi: 10.1016/j.celrep.2021.109699Banerjee H., Nieves-Rosado H., Kulkarni A., Murter B., McGrath K.V., Chandran U.R., Chang A., Szymczak-Workman A.L., Vujanovic L., Delgoffe G.M., Ferris R.L., Kane L.P. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021;36(11):109699. doi: 10.1016/j.celrep.2021.109699Roessner P.M., Llaó Cid. L., Lupar E., Roider T., Bordas M., Schifflers C., Arseni L., Gaupel A.C., Kilpert F., Krötschel M., … Seiffert M. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia. 2021;35(8):2311–2324. doi: 10.1038/s41375-021-01136-1Roessner P.M., Llaó Cid. L., Lupar E., Roider T., Bordas M., Schifflers C., Arseni L., Gaupel A.C., Kilpert F., Krötschel M., … Seiffert M. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia. 2021;35(8):2311–2324. doi: 10.1038/s41375-021-01136-1Karim R., Jordanova E.S., Piersma S.J., Kenter G.G., Chen L., Boer J.M., Melief C.J., van der Burg S.H. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res. 2009;15(20):6341–6347. doi: 10.1158/1078-0432.CCR-09-1652Karim R., Jordanova E.S., Piersma S.J., Kenter G.G., Chen L., Boer J.M., Melief C.J., van der Burg S.H. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res. 2009;15(20):6341–6347. doi: 10.1158/1078-0432.CCR-09-1652Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., Cerino A., Mondelli M.U., Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 2009;119(3):551–564. doi: 10.1172/JCI36604Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., Cerino A., Mondelli M.U., Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 2009;119(3):551–564. doi: 10.1172/JCI36604Kamada T., Togashi Y., Tay C., Ha D., Sasaki A., Nakamura Y., Sato E., Fukuoka S., Tada Y., Tanaka A., … Nishikawa H. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA. 2019;116(20):9999– 10008. doi: 10.1073/pnas.1822001116Kamada T., Togashi Y., Tay C., Ha D., Sasaki A., Nakamura Y., Sato E., Fukuoka S., Tada Y., Tanaka A., … Nishikawa H. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA. 2019;116(20):9999– 10008. doi: 10.1073/pnas.1822001116Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N., Kanto T., Ohkawa K., Hayashi N. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology. 2007;120(1):73–82. doi: 10.1111/j.1365-2567.2006.02479.xJinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N., Kanto T., Ohkawa K., Hayashi N. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology. 2007;120(1):73–82. doi: 10.1111/j.1365-2567.2006.02479.xPark H.J., Park J.S., Jeong Y.H., Son J., Ban Y.H., Lee B.H., Chen L., Chang J., Chung D.H., Choi I., Ha S.J. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. J. Immunol. 2015;194(12):5801–5811. doi: 10.4049/jimmunol.1401936Park H.J., Park J.S., Jeong Y.H., Son J., Ban Y.H., Lee B.H., Chen L., Chang J., Chung D.H., Choi I., Ha S.J. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. J. Immunol. 2015;194(12):5801–5811. doi: 10.4049/jimmunol.1401936Sega E.I., Leveson-Gower D.B., Florek M., Schneidawind D., Luong R.H., Negrin R.S. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One. 2014;9(1):e86551. doi: 10.1371/journal.pone.0086551Sega E.I., Leveson-Gower D.B., Florek M., Schneidawind D., Luong R.H., Negrin R.S. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One. 2014;9(1):e86551. doi: 10.1371/journal.pone.0086551Do J.S., Visperas A., Sanogo Y.O., Bechtel J.J., Dvorina N., Kim S., Jang E., Stohlman S.A., Shen B., Fairchild R.L., Baldwin W.M III., Vignali D.A., Min B. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal. Immunol. 2016;9(1):137–145. doi: 10.1038/mi.2015.45Do J.S., Visperas A., Sanogo Y.O., Bechtel J.J., Dvorina N., Kim S., Jang E., Stohlman S.A., Shen B., Fairchild R.L., Baldwin W.M III., Vignali D.A., Min B. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. Mucosal. Immunol. 2016;9(1):137–145. doi: 10.1038/mi.2015.45Chen X., Fosco D., Kline D.E., Meng L., Nishi S., Savage P.A., Kline J. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur. J. Immunol. 2014;44(9):2603–2616. doi: 10.1002/eji.201344423Chen X., Fosco D., Kline D.E., Meng L., Nishi S., Savage P.A., Kline J. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur. J. Immunol. 2014;44(9):2603–2616. doi: 10.1002/eji.201344423Stathopoulou C., Gangaplara A., Mallett G., Flomerfelt F.A., Liniany L.P., Knight D., Samsel L.A., Berlinguer-Palmini R., Yim J.J., Felizardo T.C., … Amarnath S. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells. Immunity. 2018;49(2):247–263.e7. doi: 10.1016/j.immuni.2018.05.006Stathopoulou C., Gangaplara A., Mallett G., Flomerfelt F.A., Liniany L.P., Knight D., Samsel L.A., Berlinguer-Palmini R., Yim J.J., Felizardo T.C., … Amarnath S. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells. Immunity. 2018;49(2):247–263.e7. doi: 10.1016/j.immuni.2018.05.006Dong Y., Han Y., Huang Y., Jiang S., Huang Z., Chen R., Yu Z., Yu K., Zhang S. PD-L1 Is Expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia. Front. Immunol. 2020;11:1710. doi: 10.3389/fimmu.2020.01710Dong Y., Han Y., Huang Y., Jiang S., Huang Z., Chen R., Yu Z., Yu K., Zhang S. PD-L1 Is Expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia. Front. Immunol. 2020;11:1710. doi: 10.3389/fimmu.2020.01710Ellestad K.K., Thangavelu G., Ewen C.L., Boon L., Anderson C.C. PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells. Eur. J. Immunol. 2014;44(12):3560–3572. doi: 10.1002/eji.201444688Ellestad K.K., Thangavelu G., Ewen C.L., Boon L., Anderson C.C. PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells. Eur. J. Immunol. 2014;44(12):3560–3572. doi: 10.1002/eji.201444688Lowther D.E., Goods B.A., Lucca L.E., Lerner B.A., Raddassi K., van Dijk D., Hernandez A.L., Duan X., Gunel M., Coric V., … Hafler D.A. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935. doi: 10.1172/jci.insight.85935Lowther D.E., Goods B.A., Lucca L.E., Lerner B.A., Raddassi K., van Dijk D., Hernandez A.L., Duan X., Gunel M., Coric V., … Hafler D.A. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935. doi: 10.1172/jci.insight.85935Wang W., Lau R., Yu D., Zhu W., Korman A., Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 2009;21(9):1065–1077. doi: 10.1093/intimm/dxp072Wang W., Lau R., Yu D., Zhu W., Korman A., Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 2009;21(9):1065–1077. doi: 10.1093/intimm/dxp072McGee H.S., Yagita H., Shao Z., Agrawal D.K. Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma. Am. J. Respir. Cell Mol. Biol. 2010;43(4):432–442. doi: 10.1165/rcmb.2009-0258OCMcGee H.S., Yagita H., Shao Z., Agrawal D.K. Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma. Am. J. Respir. Cell Mol. Biol. 2010;43(4):432–442. doi: 10.1165/rcmb.2009-0258OCYoshida K., Okamoto M., Sasaki J., Kuroda C., Ishida H., Ueda K., Ideta H., Kamanaka T., Sobajima A., Takizawa T., … Saito N. Anti-PD-1 antibody decreas es tumour-infiltrating regulatory T cells. BMC Cancer. 2020;20(1):25. doi: 10.1186/s12885-019-6499-yYoshida K., Okamoto M., Sasaki J., Kuroda C., Ishida H., Ueda K., Ideta H., Kamanaka T., Sobajima A., Takizawa T., … Saito N. Anti-PD-1 antibody decreas es tumour-infiltrating regulatory T cells. BMC Cancer. 2020;20(1):25. doi: 10.1186/s12885-019-6499-yPeligero C., Argilaguet J., Güerri-Fernandez R., Torres B., Ligero C., Colomer P., Plana M., Knobel H., García F., Meyerhans A. PD-l1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia. PLoS Pathog. 2015;11(12):e1005270. doi: 10.1371/journal.ppat.1005270Peligero C., Argilaguet J., Güerri-Fernandez R., Torres B., Ligero C., Colomer P., Plana M., Knobel H., García F., Meyerhans A. PD-l1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia. PLoS Pathog. 2015;11(12):e1005270. doi: 10.1371/journal.ppat.1005270Dodagatta-Marri E., Meyer D.S., Reeves M.Q., Paniagua R., To M.D., Binnewies M., Broz M.L., Mori H., Wu D., Adoumie M., … Akhurst R.J. б-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by б-TGFв antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer. 2019;7(1):62. doi: 10.1186/s40425-018-0493-9Dodagatta-Marri E., Meyer D.S., Reeves M.Q., Paniagua R., To M.D., Binnewies M., Broz M.L., Mori H., Wu D., Adoumie M., … Akhurst R.J. б-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by б-TGFв antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer. 2019;7(1):62. doi: 10.1186/s40425-018-0493-9Vick S.C., Kolupaev O.V., Perou C.M., Serody J.S. Anti-PD-1 checkpoint therapy can promote the function and survival of regulatory T cells. J. Immunol. 2021;207(10):2598–2607. doi: 10.4049/jimmunol.2001334Vick S.C., Kolupaev O.V., Perou C.M., Serody J.S. Anti-PD-1 checkpoint therapy can promote the function and survival of regulatory T cells. J. Immunol. 2021;207(10):2598–2607. doi: 10.4049/jimmunol.2001334Wakiyama H., Kato T., Furusawa A., Okada R., Inagaki F., Furumoto H., Fukushima H., Okuyama S., Choyke P.L., Kobayashi H. Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after PD-1 blockade therapy. Cancer Immunol. Res. 2022;10(11):1386–1397. doi: 10.1158/2326-6066.CIR-22-0041Wakiyama H., Kato T., Furusawa A., Okada R., Inagaki F., Furumoto H., Fukushima H., Okuyama S., Choyke P.L., Kobayashi H. Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after PD-1 blockade therapy. Cancer Immunol. Res. 2022;10(11):1386–1397. doi: 10.1158/2326-6066.CIR-22-0041van Gulijk M., van Krimpen A., Schetters S., Eterman M., van Elsas M., Mankor J., Klaase L., de Bruijn M., van Nimwegen M., van Tienhoven T., … van Hall T. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci. Immunol. 2023;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173van Gulijk M., van Krimpen A., Schetters S., Eterman M., van Elsas M., Mankor J., Klaase L., de Bruijn M., van Nimwegen M., van Tienhoven T., … van Hall T. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci. Immunol. 2023;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173Kumagai S., Togashi Y., Kamada T., Sugiyama E., Nishinakamura H., Takeuchi Y., Vitaly K., Itahashi K., Maeda Y., Matsui S., … Nishikawa H. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 2020;21(11):1346–1358. doi: 10.1038/s41590-020-0769-3Kumagai S., Togashi Y., Kamada T., Sugiyama E., Nishinakamura H., Takeuchi Y., Vitaly K., Itahashi K., Maeda Y., Matsui S., … Nishikawa H. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 2020;21(11):1346–1358. doi: 10.1038/s41590-020-0769-3Rauch D.A., Conlon K.C., Janakiram M., Brammer J.E., Harding J.C., Ye B.H., Zang X., Ren X., Olson S., Cheng X., … Ratner L. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019;134(17):1406– 1414. doi: 10.1182/blood.2019002038Rauch D.A., Conlon K.C., Janakiram M., Brammer J.E., Harding J.C., Ye B.H., Zang X., Ren X., Olson S., Cheng X., … Ratner L. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019;134(17):1406– 1414. doi: 10.1182/blood.2019002038Kumagai S., Koyama S., Itahashi K., Tanegashima T., Lin Y.T., Togashi Y., Kamada T., Irie T., Okumura G., Kono H., … Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201–218.e9. doi: 10.1016/j.ccell.2022.01.001Kumagai S., Koyama S., Itahashi K., Tanegashima T., Lin Y.T., Togashi Y., Kamada T., Irie T., Okumura G., Kono H., … Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201–218.e9. doi: 10.1016/j.ccell.2022.01.001Tawbi H.A., Schadendorf D., Lipson E.J., Ascierto P.A., Matamala L., Castillo Gutiérrez E., Rutkowski P., Gogas H.J., Lao C.D., de Menezes J.J., … RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 2022;386(1):24–34. doi: 10.1056/NEJMoa2109970Tawbi H.A., Schadendorf D., Lipson E.J., Ascierto P.A., Matamala L., Castillo Gutiérrez E., Rutkowski P., Gogas H.J., Lao C.D., de Menezes J.J., … RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 2022;386(1):24–34. doi: 10.1056/NEJMoa2109970Zhang Q., Chikina M., Szymczak-Workman A.L., Horne W., Kolls J.K., Vignali K.M., Normolle D., Bettini M., Workman C.J., Vignali D.A.A. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci. Immunol. 2017;2(9):eaah4569. doi: 10.1126/sciimmunol.aah4569Zhang Q., Chikina M., Szymczak-Workman A.L., Horne W., Kolls J.K., Vignali K.M., Normolle D., Bettini M., Workman C.J., Vignali D.A.A. LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci. Immunol. 2017;2(9):eaah4569. doi: 10.1126/sciimmunol.aah4569Cai L., Li Y., Tan J., Xu L., Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 2023;16(1):101. doi: 10.1186/ s13045-023-01499-1. Erratum in: J. Hematol. Oncol. 2023;16(1):105.Cai L., Li Y., Tan J., Xu L., Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 2023;16(1):101. doi: 10.1186/ s13045-023-01499-1. Erratum in: J. Hematol. Oncol. 2023;16(1):105.Gao X., Zhu Y., Li G., Huang H., Zhang G., Wang F., Sun J., Yang Q., Zhang X., Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676. doi: 10.1371/journal.pone.0030676Gao X., Zhu Y., Li G., Huang H., Zhang G., Wang F., Sun J., Yang Q., Zhang X., Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676. doi: 10.1371/journal.pone.0030676Sakuishi K., Ngiow S.F., Sullivan J.M., Teng M.W., Kuchroo V.K., Smyth M.J., Anderson A.C. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849. doi: 10.4161/onci.23849Sakuishi K., Ngiow S.F., Sullivan J.M., Teng M.W., Kuchroo V.K., Smyth M.J., Anderson A.C. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849. doi: 10.4161/onci.23849Bu M., Shen Y., Seeger W.L., An S., Qi R., Sanderson J.A., Cai Y. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tumour. Biol. 2016;37(3):3949–3956. doi: 10.1007/s13277-015-4237-xBu M., Shen Y., Seeger W.L., An S., Qi R., Sanderson J.A., Cai Y. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tumour. Biol. 2016;37(3):3949–3956. doi: 10.1007/s13277-015-4237-xPang N., Alimu X., Chen R., Muhashi M., Ma J., Chen G., Zhao F., Wang L., Qu J., Ding J. Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. 2021;35(7):e21556. doi: 10.1096/fj.202100013RPang N., Alimu X., Chen R., Muhashi M., Ma J., Chen G., Zhao F., Wang L., Qu J., Ding J. Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. 2021;35(7):e21556. doi: 10.1096/fj.202100013RLiu Z., McMichael E.L., Shayan G., Li J., Chen K., Srivastava R., Kane L.P., Lu B., Ferris R.L. Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Clin. Cancer Res. 2018;24(18):4529– 4538. doi: 10.1158/1078-0432.CCR-17-1350Liu Z., McMichael E.L., Shayan G., Li J., Chen K., Srivastava R., Kane L.P., Lu B., Ferris R.L. Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Clin. Cancer Res. 2018;24(18):4529– 4538. doi: 10.1158/1078-0432.CCR-17-1350Liu J.F., Wu L., Yang L.L., Deng W.W., Mao L., Wu H., Zhang W.F., Sun Z.J. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J. Exp. Clin. Cancer Res. 2018;37(1):44. doi: 10.1186/s13046-018-0713-7Liu J.F., Wu L., Yang L.L., Deng W.W., Mao L., Wu H., Zhang W.F., Sun Z.J. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J. Exp. Clin. Cancer Res. 2018;37(1):44. doi: 10.1186/s13046-018-0713-7Oweida A., Hararah M.K., Phan A., Binder D., Bhatia S., Lennon S., Bukkapatnam S., van Court B., Uyanga N., Darragh L., … Karam S.D. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin. Cancer Res. 2018; 24(21):5368–5380. doi: 10.1158/1078-0432.CCR-18-1038Oweida A., Hararah M.K., Phan A., Binder D., Bhatia S., Lennon S., Bukkapatnam S., van Court B., Uyanga N., Darragh L., … Karam S.D. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin. Cancer Res. 2018; 24(21):5368–5380. doi: 10.1158/1078-0432.CCR-18-1038Fuhrman C.A., Yeh W.I., Seay H.R., Saikumar Lakshmi P., Chopra G., Zhang L., Perry D.J., McClymont S.A., Yadav M., Lopez M.C., … Brusko T.M. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J. Immunol. 2015;195(1):145–155. doi: 10.4049/jimmunol.1402381Fuhrman C.A., Yeh W.I., Seay H.R., Saikumar Lakshmi P., Chopra G., Zhang L., Perry D.J., McClymont S.A., Yadav M., Lopez M.C., … Brusko T.M. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J. Immunol. 2015;195(1):145–155. doi: 10.4049/jimmunol.1402381Fourcade J., Sun Z., Chauvin J.M., Ka M., Davar D., Pagliano O., Wang H., Saada S., Menna C., Amin R., … Zarour H.M. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 2018;3(14):e121157. doi: 10.1172/jci.insight.121157Fourcade J., Sun Z., Chauvin J.M., Ka M., Davar D., Pagliano O., Wang H., Saada S., Menna C., Amin R., … Zarour H.M. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 2018;3(14):e121157. doi: 10.1172/jci.insight.121157Chen F., Xu Y., Chen Y., Shan S. TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model. Cancer Med. 2020;9(10):3584–3591. doi: 10.1002/cam4.2976Chen F., Xu Y., Chen Y., Shan S. TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model. Cancer Med. 2020;9(10):3584–3591. doi: 10.1002/cam4.2976Preillon J., Cuende J., Rabolli V., Garnero L., Mercier M., Wald N, Pappalardo A., Denies S., Jamart D., Michaux A.C., … Hoofd C. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. Mol. Cancer Ther. 2021;20(1):121–131. doi: 10.1158/1535-7163.MCT-20-0464Preillon J., Cuende J., Rabolli V., Garnero L., Mercier M., Wald N, Pappalardo A., Denies S., Jamart D., Michaux A.C., … Hoofd C. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. Mol. Cancer Ther. 2021;20(1):121–131. doi: 10.1158/1535-7163.MCT-20-0464Zeng Q., Yuan X., Cao J., Zhao X., Wang Y., Liu B., Liu W., Zhu Z., Dou J. Mycophenolate mofetil enhances the effects of tacrolimus on the inhibitory function of regulatory T cells in patients after liver transplantation via PD-1 and TIGIT receptors. Immunopharmacol. Immunotoxicol. 2021;43(2):239–246. doi: 10.1080/08923973.2021.1891247.Zeng Q., Yuan X., Cao J., Zhao X., Wang Y., Liu B., Liu W., Zhu Z., Dou J. Mycophenolate mofetil enhances the effects of tacrolimus on the inhibitory function of regulatory T cells in patients after liver transplantation via PD-1 and TIGIT receptors. Immunopharmacol. Immunotoxicol. 2021;43(2):239–246. doi: 10.1080/08923973.2021.1891247.

The authors declare that there are no conflicts of interest present.